From cell signaling to novel therapeutic concepts: international pemphigus meeting on advances in pemphigus research and therapy.

[1]  A. Troxel,et al.  Reliability and convergent validity of two outcome instruments for pemphigus. , 2009, The Journal of investigative dermatology.

[2]  S. Kojima,et al.  Desmoglein 1–dependent suppression of EGFR signaling promotes epidermal differentiation and morphogenesis , 2009, The Journal of cell biology.

[3]  H. Mouquet,et al.  ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. , 2009, Archives of dermatology.

[4]  H. Shimizu,et al.  A randomized double-blind trial of intravenous immunoglobulin for pemphigus. , 2009, Journal of the American Academy of Dermatology.

[5]  R. Eming,et al.  B-cell-directed therapy for inflammatory skin diseases. , 2009, The Journal of investigative dermatology.

[6]  D. Murrell,et al.  Interventions for pemphigus vulgaris and pemphigus foliaceus. , 2009, The Cochrane database of systematic reviews.

[7]  R. Eming,et al.  Clinical and Immunological Follow-Up of Pemphigus Patients on Adjuvant Treatment with Immunoadsorption or Rituximab , 2008, Dermatology.

[8]  R. Eming,et al.  Rituximab exerts a dual effect in pemphigus vulgaris. , 2008, The Journal of investigative dermatology.

[9]  H. Shimizu,et al.  Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. , 2008, Journal of the American Academy of Dermatology.

[10]  G. Burmester,et al.  New approaches of B-cell-directed therapy: beyond rituximab , 2008, Current opinion in rheumatology.

[11]  D. Zillikens,et al.  Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins , 2007, The British journal of dermatology.

[12]  J. Roujeau,et al.  A single cycle of rituximab for the treatment of severe pemphigus. , 2007, The New England journal of medicine.

[13]  A. Theofilopoulos,et al.  Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. , 2007, Clinical immunology.

[14]  R. Paus,et al.  Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just ‘witnesses of disease'? , 2006, Experimental Dermatology.

[15]  R. Eming,et al.  T cell control in autoimmune bullous skin disorders. , 2006, The Journal of clinical investigation.

[16]  D. Cines,et al.  Mechanisms of Action of Therapeutics in Idiopathic Thrombocytopenic Purpura , 2003, Journal of pediatric hematology/oncology.

[17]  T. Nishikawa,et al.  Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model. , 2006, The Journal of investigative dermatology.